Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Nebhan on the Efficacy of Checkpoint Inhibitors in Older Patients With Cancer

November 19th 2021

Caroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.

Dr. Ramnaraign on Current Treatment Guidelines for First-Line Metastatic RCC

November 18th 2021

Brian Ramnaraign, MD, discusses current first-line treatment guidelines for patients with metastatic renal cell carcinoma.

FDA Approves Adjuvant Pembrolizumab for RCC

November 18th 2021

The FDA has approved pembrolizumab for the adjuvant treatment of patients with renal cell carcinoma who are at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

Subsequent-line Treatment in Advanced RCC Leaves Room for Personalization

November 17th 2021

For patients with advanced clear cell renal cell carcinoma, it will be of utmost importance to recognize the variation in response and type of progression with first-line therapy, the patient’s characteristics and motivations, and the promise of new agents and combinations.

Dr. Bupathi on First-Line Treatment Options for Clear Cell RCC

November 16th 2021

Manojkumar Bupathi, MD, MS, discusses the improvement in first-line treatment options for patients with clear cell renal cell carcinoma.

Patients with RCC, Melanoma Taking ICIs Can Safely Receive COVID-19 Vaccination

November 15th 2021

The COVID-19 vaccine was safe and well tolerated in patients who received immune checkpoint inhibitors for renal cell carcinoma or melanoma.

Investigators Set Their Sights on Optimizing Sequencing With Novel Therapies in GU Cancers

November 12th 2021

Treatment selection and sequencing in genitourinary cancers, such as metastatic bladder cancer and metastatic renal cell carcinoma, have become more complicated and require nuanced decision making.

Dr. Michalski on the Goals ASTRO in Radiation Oncology

November 11th 2021

Jeff Michalski, MD, MBA, FASTRO, discusses the goals of the American Society for Radiation Oncology in radiation oncology.

Dr. Yentz on Unmet Needs in Metastatic RCC

November 11th 2021

Sarah Elizabeth Yentz, MD, discusses unmet needs in metastatic renal cell carcinoma.

Dr. Palmbos on the Role of Chemoimmunotherapy in Bladder Cancer

November 11th 2021

Phillip Palmbos, MD, PhD, discusses the role of chemoimmunotherapy in patients with bladder cancer.

Recent Developments Solidify Role of Immunotherapy in Advanced Urothelial Carcinoma

November 11th 2021

Matthew Galsky, MD, discusses the role of immunotherapy in urothelial cancer, as well as unmet needs and future research directions for this patient population.

FDA Clears IND to Expand ABILITY Trial Examining MDNA11 in Solid Tumors to the United States

November 9th 2021

The FDA has greenlit an investigation new drug application to expand the ongoing phase 1/2 ABILITY trial, which is evaluating the beta-only IL-2 superagonist MDNA11 in patients with solid tumors, to clinical trial sites in the United States.

Tagawa Breaks Down FGFR Testing and the Use of Erdafitinib in Bladder Cancer

November 8th 2021

Dr. Tagawa discusses the incidence and identification of FGFR alterations in bladder cancer, the approval and use of erdafitinib in the second-line setting for patients with advanced bladder cancer, and research directions with the FGFR inhibitor in the field.

Regulatory Discussions Continue Regarding BLA for Vicineum in BCG-Unresponsive NMIBC

November 2nd 2021

Sesen Bio met with the FDA to discuss questions related to the Chemistry, Manufacturing, and Controls that were raised in the complete response letter previously issued by the regulatory agency regarding the biologics license application for Vicineum as a potential treatment for patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.

Dr. Palmbos on Frontline Treatment Recommendations in Bladder Cancer

November 2nd 2021

Phillip Palmbos, MD, PhD, discusses updates and therapeutic recommendations for the frontline treatment of patients with bladder cancer.

Definitive Radiotherapy Shows Promise as Alternative to Systemic Therapy in Oligometastatic RCC

November 1st 2021

Sequential radiotherapy demonstrated preliminary efficacy and safety as a potential alternative to systemic therapy in patients with oligometastatic renal cell carcinoma.

Dr. Yentz on Navigating Frontline Treatment Selection in RCC

November 1st 2021

Sarah Elizabeth Yentz, MD, discusses navigating frontline treatment selection in renal cell carcinoma.

Research Efforts Seek to Understand Biology, Genomic Driver of Translocation RCC

October 27th 2021

Ziad Bakouny, MD, MSc, discusses recent ongoing research into the genomic drivers and biology of tRCC that could lead to improved outcomes for patients.

Top Takeaways on Key GU Research From the 2021 ESMO Congress

October 27th 2021

We spotlight key data presented during the 2021 ESMO Congress in kidney cancer, prostate cancer, and bladder cancer.

Scope of Treatment Sequencing Grows in Genitourinary Malignancies

October 26th 2021

Jonathan A. Chatzkel, MD, discusses updates in first-line treatment options for metastatic urothelial cancer, as well as recommended treatments for patients with previously treated, locally advanced or metastatic urothelial cancer, and also newly diagnosed metastatic renal cell carcinoma.